Talc-Cancer Lawsuits Play Critical Role in Exposing Johnson & Johnson's Unethical Experiments on Prisoners

Revelations that Johnson & Johnson (NYSE: JNJ) paid scientific researchers to conduct unethical and inhumane experiments on prisoners in the 1960s are shedding new light on what the company knew about cancer risks from its talc-based products like the iconic Johnson's Baby Powder, just as the company is moving to shut down jury trials in a controversial bankruptcy gambit.

Details about experiments paid for by J&J at Holmesburg Prison in Pennsylvania in the 1960s are coming to light only because cancer victims have been allowed to seek justice through their Seventh Amendment right to a jury trial, says trial lawyer Majed Nachawati , founder of Dallas -based Fears Nachawati. Future trials are in jeopardy now that J&J has initiated a controversial bankruptcy in which tens of thousands of cancer lawsuits have been transferred to a shell company that has since declared bankruptcy.

Mr. Nachawati's law firm represents numerous women who have been diagnosed with ovarian cancer after years of using Johnson's Baby Powder and other talc products produced by the company. He called on lawmakers to write legislation that would close the loophole that allows profitable companies to shed their legal liabilities in bankruptcy.

"Every cancer victim has a right to have their case heard by a jury," he says. "The idea that bankruptcy laws were passed to allow a Fortune 20 company to shed its liability through bankruptcy when that company is not in financial distress is concerning and renders toothless the right to a trial by jury. Americans should call on all lawmakers to prohibit the reprehensible conduct that Johnson & Johnson and its shell companies have implemented by filing bankruptcy."

Revelations reported by Bloomberg News show that J&J funded research in which primarily African-American inmates were injected with talc or asbestos to study their bodies' reactions. The reports indicate that J&J was aware of the health risks of its talc products for decades but has never placed a warning label on those products

"The world needs to know, and litigation is the only way that this information is coming out," Mr. Nachawati says.

Fears Nachawati Law Firm represents individuals in mass-tort litigation, businesses and governmental entities in contingent litigation and individual victims in complex personal injury litigation. One of the largest and most diverse products liability law firms in the nation, Fears Nachawati was ranked No. 1 nationally in products liability filings in federal court over the past three years, according to Lex Machina. For more information visit https://www.fnlawfirm.com .

Contact:
Robert Tharp
214-420-6011
robert@androvett.com

Cision View original content: https://www.prnewswire.com/news-releases/talc-cancer-lawsuits-play-critical-role-in-exposing-johnson--johnsons-unethical-experiments-on-prisoners-301499229.html

SOURCE Fears Nachawati Law Firm

News Provided by PR Newswire via QuoteMedia

JNJ
The Conversation (0)
doctor with hands together, palms up below digital medical symbols

Innovations and Opportunities in European Healthcare Technologies

In recent years, European companies have emerged as trailblazers in healthcare technology, effectively changing the face of health and patient care. Through innovation, they're not only improving systems, processes and patient outcomes but also saving lives.These advanced European technologies... Keep Reading...
Johnson & Johnson to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

Johnson & Johnson to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 44 th Annual Global Healthcare Conference on Tuesday, June 13 th , at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, CA. Biljana Naumovic, Worldwide Vice President, Oncology, and Peter Lebowitz, Global... Keep Reading...
Johnson & Johnson and Kenvue Announce Pricing of Upsized Kenvue Inc. Initial Public Offering

Johnson & Johnson and Kenvue Announce Pricing of Upsized Kenvue Inc. Initial Public Offering

Johnson & Johnson (NYSE: JNJ) and Kenvue Inc. ("Kenvue"), a wholly owned subsidiary of Johnson & Johnson, today announced the pricing of Kenvue's upsized initial public offering ("IPO") of 172,812,560 shares of Kenvue's common stock at a price to the public of $22.00 per share. In addition,... Keep Reading...
Johnson & Johnson to Participate in the Bernstein 39th Annual Strategic Decisions Conference

Johnson & Johnson to Participate in the Bernstein 39th Annual Strategic Decisions Conference

Johnson & Johnson (NYSE: JNJ) will participate in the Bernstein 39 th Annual Strategic Decisions Conference on Wednesday, May 31 st , at the New York Hilton Midtown in New York. Joaquin Duato, Chairman of the Board and Chief Executive Officer will represent the Company in a session scheduled at... Keep Reading...

Kaleido Collaborates with Janssen on Metabolic Therapies

Kaleido Biosciences (NADAQ:KLDO) announced a research collaboration with Janssen’s World Without Disease Accelerator, part of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE:JNJ). As quoted in the press release: The collaboration will explore the potential for Kaleido’s... Keep Reading...
Medical devices on a desk.

How to Invest in Medical Device Stocks and ETFs

The medical device market offers investors unique exposure to the overall life science space, especially in an era of fast-growing tech advancements in healthcare.This industry covers a wide range of health and medical instruments and equipment used in the treatment, mitigation, diagnosis and... Keep Reading...
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians. BlinkLab states in its Wednesday (March 12) release that the study is the largest digital... Keep Reading...
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at... Keep Reading...
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or... Keep Reading...
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the... Keep Reading...
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries CommenceDownload the PDF here. Keep Reading...

Latest Press Releases

Related News